News & Events about Collegium Pharmaceutical Inc.
Highlights 2022 environmental, social and governance achievementsSTOUGHTON, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced the release of its inaugural Environmental, Social and ...
STOUGHTON, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the pricing of its offering of $210,000,000 aggregate principal amount of 2.875% convertible senior notes due 2029 (the notes) in a private offering to qualified institutional buyers ...
Product Revenues, Net Expected in the Range of $565.0 Million to $580.0 Million Adjusted Operating Expenses* Expected in the Range of $135.0 Million to $145.0 Million Adjusted EBITDA* Expected in the Range of $355.0 Million to $370.0 Million $100 Million Share Repurchase Program Authorized by the ...
Mike Heffernan appointed Chairman of NMD Pharmas Board of Directors Brings 30 years of experience building private and public development-stage and commercial biopharmaceutical companies and has overseen several successful IPOs and trade sales Aarhus, Denmark, 3 January 2023 NMD Pharma A/S, a ...
Ruling bars ANDA filer Alvogen from entering market until 2032 patent expirySTOUGHTON, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the Federal Circuit has upheld the judgment of ...